BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9373755)

  • 1. Mack Forster Award Lecture. Receptor nuclear medicine: vasointestinal peptide and somatostatin receptor scintigraphy for diagnosis and treatment of tumour patients.
    Virgolini I
    Eur J Clin Invest; 1997 Oct; 27(10):793-800. PubMed ID: 9373755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imaging tumors with peptide-based radioligands.
    Behr TM; Gotthardt M; Barth A; Béhé M
    Q J Nucl Med; 2001 Jun; 45(2):189-200. PubMed ID: 11476170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo studies of three radiolabelled somatostatin analogues: 123I-octreotide (OCT), 123I-Tyr-3-OCT and 111In-DTPA-D-Phe-1-OCT.
    Virgolini I; Angelberger P; Li S; Yang Q; Kurtaran A; Raderer M; Neuhold N; Kaserer K; Leimer M; Peck-Radosavljevic M; Scheithauer W; Niederle B; Eichler HG; Valent P
    Eur J Nucl Med; 1996 Oct; 23(10):1388-99. PubMed ID: 8781146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasoactive intestinal peptide receptor scintigraphy in patients with pancreatic adenocarcinomas or neuroendocrine tumours.
    Hessenius C; Bäder M; Meinhold H; Böhmig M; Faiss S; Reubi JC; Wiedenmann B
    Eur J Nucl Med; 2000 Nov; 27(11):1684-93. PubMed ID: 11105825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.
    Virgolini I; Raderer M; Kurtaran A; Angelberger P; Banyai S; Yang Q; Li S; Banyai M; Pidlich J; Niederle B; Scheithauer W; Valent P
    N Engl J Med; 1994 Oct; 331(17):1116-21. PubMed ID: 7935635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-D-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-D-Phe1-octreotide.
    Bangard M; Béhé M; Guhlke S; Otte R; Bender H; Maecke HR; Biersack HJ
    Eur J Nucl Med; 2000 Jun; 27(6):628-37. PubMed ID: 10901448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
    Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
    Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract.
    Virgolini I; Raderer M; Kurtaran A; Angelberger P; Yang Q; Radosavljevic M; Leimer M; Kaserer K; Li SR; Kornek G; Hübsch P; Niederle B; Pidlich J; Scheithauer W; Valent P
    Nucl Med Biol; 1996 Aug; 23(6):685-92. PubMed ID: 8940711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide receptors in gut endocrine tumours.
    de Herder WW; Hofland LJ; van der Lely AJ; Lamberts SW
    Baillieres Clin Gastroenterol; 1996 Dec; 10(4):571-87. PubMed ID: 9113313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
    Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
    Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging.
    Reubi JC
    J Nucl Med; 1995 Oct; 36(10):1846-53. PubMed ID: 7562054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829.
    Virgolini I; Leimer M; Handmaker H; Lastoria S; Bischof C; Muto P; Pangerl T; Gludovacz D; Peck-Radosavljevic M; Lister-James J; Hamilton G; Kaserer K; Valent P; Dean R
    Cancer Res; 1998 May; 58(9):1850-9. PubMed ID: 9581824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New trends in peptide receptor radioligands.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Andreae F; Kurtaran A; Dudczak R
    Q J Nucl Med; 2001 Jun; 45(2):153-9. PubMed ID: 11476164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
    Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
    Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification.
    Reubi JC; Waser B; Laissue JA; Gebbers JO
    Cancer Res; 1996 Apr; 56(8):1922-31. PubMed ID: 8620515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
    Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
    Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.
    Krenning EP; Kwekkeboom DJ; Bakker WH; Breeman WA; Kooij PP; Oei HY; van Hagen M; Postema PT; de Jong M; Reubi JC
    Eur J Nucl Med; 1993 Aug; 20(8):716-31. PubMed ID: 8404961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [111-indium DTPA octreotide scintigraphy in colorectal liver metastases].
    Seifert JK; Görges R; Bockisch A; Junginger T
    Langenbecks Arch Chir; 1997; 382(6):332-6. PubMed ID: 9498205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of iodine-123-vasoactive intestinal peptide receptor scintigraphy and indium-111-CYT-103 immunoscintigraphy.
    Raderer M; Becherer A; Kurtaran A; Angelberger P; Li S; Leimer M; Weinlaender G; Kornek G; Kletter K; Scheithauer W; Virgolini I
    J Nucl Med; 1996 Sep; 37(9):1480-7. PubMed ID: 8790198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
    Behr TM; Béhé M; Becker W
    Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.